Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,922
  • Shares Outstanding, K 2,766
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,300 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.98
  • Most Recent Earnings $-0.69 on 03/24/25
  • Next Earnings Date 05/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -4.59
  • Growth Rate Est. (year over year) +21,864.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6498 +6.02%
on 03/26/25
1.1000 -37.37%
on 03/12/25
-0.1351 (-16.40%)
since 02/27/25
3-Month
0.6498 +6.02%
on 03/26/25
2.5900 -73.40%
on 01/07/25
-0.9811 (-58.75%)
since 12/27/24
52-Week
0.6498 +6.02%
on 03/26/25
9.6500 -92.86%
on 04/16/24
-5.2406 (-88.38%)
since 03/27/24

Most Recent Stories

More News
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

PALI : 0.6849 (-1.45%)
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

PALI : 0.6849 (-1.45%)
Palisade Bio Participates in Virtual Investor “What This Means” Segment

PALI : 0.6849 (-1.45%)
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) 

PALI : 0.6849 (-1.45%)
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

PALI : 0.6849 (-1.45%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.3606 (+4.23%)
AREC : 0.5386 (-2.09%)
OTLK : 1.3500 (+4.65%)
AMIX : 1.9100 (+2.14%)
CNSP : 1.3100 (-7.09%)
PALI : 0.6849 (-1.45%)
NVNO : 2.85 (-1.72%)
HURA : 3.59 (+0.84%)
GRI : 5.97 (+0.33%)
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

PALI : 0.6849 (-1.45%)
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

PALI : 0.6849 (-1.45%)
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

PALI : 0.6849 (-1.45%)
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

PALI : 0.6849 (-1.45%)

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 0.7896
2nd Resistance Point 0.7526
1st Resistance Point 0.7238
Last Price 0.6849
1st Support Level 0.6580
2nd Support Level 0.6210
3rd Support Level 0.5922

See More

52-Week High 9.6500
Fibonacci 61.8% 6.2119
Fibonacci 50% 5.1499
Fibonacci 38.2% 4.0879
Last Price 0.6849
52-Week Low 0.6498

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar